SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (4)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Doria, A
Right arrow Articles by Briani, C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Doria, A
Right arrow Articles by Briani, C
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

review-article

Lupus: improving long-term prognosis

A Doria

Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy;

C Briani

Department of Neurosciences, University of Padova, Padova, Italy

Abstract

Over recent decades short- and medium-term survival has greatly improved in patients affected with systemic lupus erythematosus, but long-term prognosis still remains poor mainly due to complications of the disease and/or its treatment. To improve long-term prognosis in systemic lupus erythematosus, we should try to adopt, early in the disease course, strategies that can contribute to reducing long-term complications, including screening for and prophylaxis against infections, control of risk factors for atherosclerosis, and cancer surveillance. However, in patients with systemic lupus erythematosus all these preventive strategies are often not sufficient. Indeed, two important systemic lupus erythematosus–related factors play a relevant role in all these complications: severe disease manifestations, such as glomerulonephritis and central nervous system involvement, and corticosteroid and cyclophosphamide use. Therefore, to prevent long-term complications, we should try to control disease activity and severity using the lowest effective dosage of these drugs. Moreover, strategies directed at preventing clinical manifestations in asymptomatic antinuclear antibody–positive individuals or in antiphospholipid antibody–positive systemic lupus erythematosus patients, as well as at preventing severe manifestations in patients with mild systemic lupus erythematosus at the time of the diagnosis should be considered.

Key Words: systemic lupus erythematosus • SLE • prognosis • therapy

Lupus, Vol. 17, No. 3, 166-170 (2008)
DOI: 10.1177/0961203307087612


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
LupusHome page
G. Moroni, C. Novembrino, S. Quaglini, R. De Giuseppe, B. Gallelli, V. Uva, V. Montanari, P. Messa, and F. Bamonti
Oxidative stress and homocysteine metabolism in patients with lupus nephritis
Lupus, January 1, 2010; 19(1): 65 - 72.
[Abstract] [PDF]


Home page
The Journal of RheumatologyHome page
A. DORIA
Atherosclerosis and Lupus: What We Know and What We Should Know
J Rheumatol, November 1, 2009; 36(11): 2380 - 2382.
[Full Text] [PDF]



Advertisement